TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in sperm mitochondrial function from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Ultrasound identification of lumbar interspace
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency difference of the determinant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in severity of involuntary urine loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Level of STAT4 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain Score on Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Who Suffer Mortality, a Serious Adverse Event, or Other Adverse Event During the Study Period
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients Transplanted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Patients Who Experience Grade 3 and Above Non-Hematologic Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Total Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Dermal Closure Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction in Hamilton Depression Rating Scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Retinal nerve fiber layer average thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CDS scale evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WHO scale evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gorelick scale evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Whose Thyroid Stimulating Hormone (TSH) Levels Normalize
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Participants Whose Total Triiodothyronine (Total T3) Levels Decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Participants Whose Free Thyroxine (Free T4) Levels Decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Complications relating to sickle cell disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pain Medication Utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in reported pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in level of HIV-related neuropathic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum Tolerated Dose (MTD)
Endpoint domain: Adverse events/effects
Endpoint subdomain: Dose-limiting toxicity (DLT)
Primary endpoint: Duration of antibiotic therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Completion of the Ready for MS programme
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: reduction in self-reported pain intensity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serotype 19A-specific carriage rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep Pattern
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Bipodal and Unipodal Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isokinetic test of knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants With Clinically Significant Vital Signs Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Changes in Electrocardiograms (ECGs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall Response Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Pain Intensity measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thermal Pain threshold (HPT) and Temporal summation (HTS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cutaneous Mechanical Pain testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of B-701 in combination with Pembrolizumab
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of BEZ235
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exhaled breath hydrogen peroxide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle strength in leg extension and leg press
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change in the microvascular flow index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage Change in p-ERK H Score From Week 0 to Week 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change in p-ERK H Score From Week 8 to Week 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tunnel Widening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in GIUS parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in patient knowledge of inflammatory bowel disease
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants not alive
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Patients That Underwent an R0 Resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of CHF patients with and without acute lung accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Generalized Anxiety Disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough concentrations of PF-04531083
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in total cholesterol to HDL-C ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Synovial fluid HA concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Synovial fluid albumin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Synovial fluid lubrication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measures of pathologic remodeling (thickness-to-dimension ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Differences in serum biomarkers (cardiac troponins and natriuretic peptides)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in Unified Parkinson's Disease Rating Scale (UPDRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Geometric Mean Titers (GMTs) Against Homologous Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects Achieving Seroconversion Against Homologous Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects With HI Titers ≥40 Against Homologous Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Drop Discomfort Post Dose Instillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beta Cell Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Acute Pain Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decay extracted filled primary teeth index (deft index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: decayed missing filled permanent teeth (DMFT index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Change in provider burnout
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitivity of isolated organism to amoxicillin clavulanate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pathological complete remission (pCR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isolation of a pulmonary vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time on Treatment With EGFR-TKI
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Composite Outcome of Death (All Cause) or Cardiovascular Hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: prenatal exams, tetanus vaccinations, & iron tablets received by pregnant women
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: infant vaccinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visits by nurse midwife
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incident vertebral fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants Recruited and Administered a Medication Dose
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of new falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: preoperative maternal anxiety changes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Complete Clearance of AKs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Progression as Evaluated by the Investigator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to Progression as Evaluated by the Independent Review Committee (IRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cumulative incidence of relapses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antihemagglutinin antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Achieving target sedation level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Infusion Reactions (IR)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Occurrences of Palmar-plantar Erythrodysesthesia (PPE)
Endpoint domain: Adverse events/effects
Primary endpoint: Bone health assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Assessment of VF function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of subjective voice ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Assessment of tissue metabolism and healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adherence Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Canadian occupational performance measure score change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: histological remission of cutaneous metastatic melanoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Complete Response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: placental volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: D-Dimers rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hymenal patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax values of AC 170
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax values of AC 170
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC values of AC 170
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T 1/2 values of AC 170
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mammographically-detected breast lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Effectiveness of local anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite 1-year event rate
Endpoint domain: Mortality/survival
Primary endpoint: Change in Headache Disability Index (HDI) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean night polysomnographic wake time after sleep onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Global Outcome at 6 Months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Cardiac Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in weekly rate of student office referrals (overall)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in weekly rate of student office referrals (physical aggression)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in student K-6 stress screener score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of match lecturer's take home message
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in Cardiorespiratory Fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnostic accuracy of Spyglass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Blood flow of arteriovenous fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arteriovenous fistula dysfunction or occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AVF Maturation Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical symptoms and signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ALT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: ALP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: TBIL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Morphological changes observed via OCT and OCTA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased Back Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: LVOT obstruction degree in cm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systolic anterior motion of mitral valve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change of sleep quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change From Baseline in Abbreviated Extrapyramidal Symptom Rating Scale (ESRS-A) Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Response to Columbia-Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Amount of bone gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding Grade III and IV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Health Risk Behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adolescent Satisfaction With Care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: In-hospital major bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in cartilage thickness in the medial femoro-tibial compartment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects experiencing AIRs defined as increase of pain by 30mm on a VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety assessed by SAEs and AEs - CTCAE grading
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability assessed by SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Digit span backward test (DSB)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Diagnostic performance of contrast-enhanced ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Biomarkers for diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of Sudapyridine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach plasma Cmax (Tmax) of Sudapyridine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with adverse events (AEs) or Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants That Experienced a Dose Limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Pain Relief at Thirty Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Number of Participants With MRSA Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Observed Change in Standardized Photosensitivity Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain Uptake of [18F] Flutemetamol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Amyloid Levels in Biopsy Samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number Of Subjects Who Need To Discontinue Study Medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Intraoperative free margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Atrial Fibrillation survival
Endpoint domain: Mortality/survival
Primary endpoint: Interstitial fibrosis in kidney transplant biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in Corneal Fluorescein Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical characteristics of auto-inflammatory diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunological characteristics of auto-inflammatory diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Metabolic/endocrinological characteristics of auto-inflammatory diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Global Rating of Change Scale - assessing change in pain and function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Foot and Ankle Disability Index - assessing change in disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Numerical Rating Scale - assessing change in severity of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Change in Colony Forming Units (CFUs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of participants with adverse events (AEs) related to rilpivirine (RPV)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with AEs Leading to Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Pregnancies
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Grade 3/4 Rash Regardless of Causality
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in tumor motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Feasibility of Internet-based user environment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Area under the concentration-time curve (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Were Hospitalized and/or Died Through Day 29
Endpoint domain: Mortality/survival
Primary endpoint: Expression of senescence markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: WOMAC pain scale
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Biochemical pregnancy loss
Endpoint domain: Mortality/survival
Primary endpoint: Number of subjects with significant changes from baseline laboratory measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes